Obiltoxaximab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Chimeric (mouse/human) |
Target | Bacillus anthracis anthrax |
Clinical data | |
Trade names | Anthim |
Identifiers | |
CAS Number | 1351337-07-9 |
ATC code | None |
ChemSpider | none |
Chemical data | |
Formula | C6444H9994N1734O2022S44 |
Molar mass | 145.5 kDa |
Obiltoxaximab is a monoclonal antibody designed for the treatment of exposure to Bacillus anthracis spores (etiologic agent of anthrax).[1]
This drug was developed by Elusys Therapeutics, Inc.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Obiltoxaximab, American Medical Association.
|
This article is issued from Wikipedia - version of the Saturday, November 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.